Lundbeck, a Danish international pharmaceutical company, completed the acquisition of Alder BioPharmaceuticals, a pharmaceutical development company based in Bothell, Washington, for $2bn. The consideration represents a 79% premium to Alder's share price based on the closing price on September 13, 2019. “I am very excited to welcome Alder to Lundbeck. The completion of our acquisition of Alder with the exciting investigational drug, eptinezumab, will expand the breadth of our portfolio into migraine and represents a major step in the execution of our Expand and Invest to Grow strategy and Lundbeck can now take part in helping the migraine community where so much unmet need remains,” Deborah Dunsire, President and CEO of Lundbeck.